Precision-medicine platform for mild Alzheimer’s disease and at-risk individuals

Precision-medicine platform for mild Alzheimer’s disease and at-risk individuals

Alzheimer’s disease (AD) is a progressive, neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism. Nearly all previous single-domain studies to treat AD have failed, likely because it is a complex disease with multiple underlying drivers contributing to risk, onset, and progression. Keine et al. explored the efficacy of a multidomain therapy approach based on the disease risk factor status specific to individuals with AD diagnosis or concern.

To read the public release, click here.